Prandial Options to Advance Basal Insulin Glargine Therapy
1318 Diabetes Care Volume 39, August 2016 Julio Rosenstock,1 Bruno Guerci,2 Prandial Options to Advance Basal Markolf Hanefeld,3 Sandro Gentile,4 Ronnie Aronson,5 Francisco J. Tinahones,6 Insulin Glargine Therapy: Testing Christine Roy-Duval,7 Elisabeth Souhami,7 Marek Wardecki,8 Jenny Ye,9 Lixisenatide Plus Basal Insulin Riccardo Perfetti,9 and Simon Heller,10 on behalf of the GetGoal Duo-2 Trial Versus Insulin Glulisine Either as Investigators Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial Diabetes Care 2016;39:1318–1328 | DOI: 10.2337/dc16-0014 CLIN CARE/EDUCATION/NUTRITION/PSYCHOSOCIAL OBJECTIVE To provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in overweight patients with type 2 diabetes inadequately controlled on basal insulin glargine with or without 1–3 oral antidi- 1Dallas Diabetes and Endocrine Center at Medi- abetic agents (OADs). cal City, Dallas, TX 2University of Lorraine and the Department of RESEARCH DESIGN AND METHODS Diabetology, Metabolic Diseases and Nutrition, Brabois Adult Hospital, Vandœuvre-les-Nancy,` Patients were randomized to lixisenatide once daily or insulin glulisine given once France 3 or thrice daily, added to glargine, with or without metformin, if HbA1c remained GWT-TUD, Study Centre Prof. Hanefeld, Dres- ‡7to£9% (‡53 to £75 mmol/mol) after 12 weeks of glargine optimization with den Technical University, Dresden, Germany 4Department of Clinical and Experimental Med- OADs other than metformin stopped at the start
[Show full text]